AlgoNomics raises additional 0.5 million euro in second closing.

2 million euro investment in Immunogenicity screening technology.

Ghent, Belgium - June 27, 2007 - AlgoNomics NV, the immunoprofiling company, announced today that it raised an additional 0.5 million euro (0.6 million USD) in a second closing, bringing the total financing round to 2 million euro (2.7 million USD).
The funding is fully invested in the development of the in vitro screening platform that complements the company’s existing immunogenicity screening services and tools.

The patented Epibase^® screening tool is currently widely applied for the immunogenicity screening and optimization of biotherapeutics, such as therapeutic antibodies, biosimilars and vaccines.

According to Dr. Lasters, CEO of AlgoNomics, “This investment allows a significant growth of our in vitro assays. Moreover, it allows the further evaluation of novel technologies to address all aspects of immunogenicity.”

This second closing was subscribed by Fortis Private Equity and KBC Private Equity. The financing round was led by the new investor Baekeland II fund, and subscribed by the Gemma Frisius Funds, Flanders Institute for Biotechnology and TrustCapital. In addition, the Flanders Institute for Biotechnology (VIB) participated as well..

About Epibase

Epibase® estimates to what extent a given therapeutic protein may lead to an immune response in patients. The computer based platform focuses on T-cell epitope identification. The uniqueness of Epibase® resides in its capability to identify the T-cell epitopes specific for HLA types covering most of the human population (including Caucasian, Oriental and Afro-American), including the majority of HLA sub-types for which little or no experimental data is available.

About immunogenicity

All therapeutic proteins show some level of immunogenicity, a side effect where the patient recognizes the drug as a "foreign" substance. This causes the patient's immune system to mount a defence against the therapeutic drug, resulting in significant reduction of efficacy and a rapid clearance of the drug from the circulation. The process is driven by the presence of T-cell epitopes in the protein – fragments binding to HLA receptors and inducing a T-cell response. There is a growing consensus about the need for early adoption and standardisation of immunogenicity assessments for biologicals.

About AlgoNomics

AlgoNomics is a Belgium based biotech company providing structural bioinformatics services to develop rationally designed therapeutics in the broad field of immunotherapy. AlgoNomics owns a rich, proprietary platform for structure-based protein and peptide design. The technology platform contains innovative tools to unravel protein-protein and protein-peptide interactions. AlgoNomics’ premier product is the Epibase® platform for T-cell epitope identification in different population groups, applied in the discovery of vaccines and therapeutic proteins. For more information about AlgoNomics visit www.algonomics.com

Further information:

AlgoNomics N.V.
Philippe Stas
Chief Operating Officer
Technologiepark 4
B-9052 Gent – Belgium
Tel.:  +32.(0)9.241.11.00
Fax.:  +32.(0)9.241.11.02
Philippe.Stas@algonomics.com